Diabetes and cancer: a short review for internists
Keywords:
diabetes, cancer, insulin, insulin analogues, sulfonylureas, metforminAbstract
The risk of developing a range of cancers is moderately increased in type 1 and type 2 diabetes. Obesity, insulin resistance,
hyperinsulinemia, and diabetes therapy with insulin, insulin
analogues and sulfonylureas may be responsible for this fact.
Metformin seems to have a protective effect. We examined all
these aspects, and believe that the current aetiopathogenic link
among diabetes, diabetes treatment and cancer is tenuous, further
studies are necessary
Downloads
References
Smith U, Gale EAM. Does diabetes therapie influence the risk of cancer? Diabetologia 2009; 52: 1699-1708.
Zendehdel K, Nyrén O, Östenson C-G, Adami H-O, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003; 95: 1797-1800.
Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk among patients hospitalized for type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med 2010; 27: 791-797.
Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology 2007; 132: 2208-2225.
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60: 207-221.
Draznin B. Mitogenic action of insulin: friend, foe or “frenemy”? Diabetologia 2010; 53: 229-233.
Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-1744.
Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies: a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-1754.
Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
Colhoun HM, SDRN Epidemiology group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52: 1755-1765.
Müssig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Häring H-U. Diabetes, Insulin, Insulinanaloga und Karzinome. Dtsch Med Wochenschr
; 135: 924-929.
Home PD, Langarenne P. Combined randomized controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52; 2499-2506.
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
